224 related articles for article (PubMed ID: 24101516)
1. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.
Donaldson JM; Zer C; Avery KN; Bzymek KP; Horne DA; Williams JC
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17456-61. PubMed ID: 24101516
[TBL] [Abstract][Full Text] [Related]
2. Engineering a high-affinity peptide binding site into the anti-CEA mAb M5A.
Zer C; Avery KN; Meyer K; Goodstein L; Bzymek KP; Singh G; Williams JC
Protein Eng Des Sel; 2017 Jun; 30(6):409-417. PubMed ID: 28431161
[TBL] [Abstract][Full Text] [Related]
3. Refining the Quality of Monoclonal Antibodies: Grafting Unique Peptide-Binding Site in the Fab Framework.
King JD; Williams JC
Methods Mol Biol; 2019; 1904():293-298. PubMed ID: 30539475
[TBL] [Abstract][Full Text] [Related]
4. Mechanically interlocked functionalization of monoclonal antibodies.
Bzymek KP; Puckett JW; Zer C; Xie J; Ma Y; King JD; Goodstein LH; Avery KN; Colcher D; Singh G; Horne DA; Williams JC
Nat Commun; 2018 Apr; 9(1):1580. PubMed ID: 29679060
[TBL] [Abstract][Full Text] [Related]
5. Development of a high affinity, non-covalent biologic to add functionality to Fabs.
Avery KN; Zer C; Bzymek KP; Williams JC
Sci Rep; 2015 Jan; 5():7817. PubMed ID: 25588710
[TBL] [Abstract][Full Text] [Related]
6. Natural and non-natural amino-acid side-chain substitutions: affinity and diffraction studies of meditope-Fab complexes.
Bzymek KP; Avery KA; Ma Y; Horne DA; Williams JC
Acta Crystallogr F Struct Biol Commun; 2016 Nov; 72(Pt 11):820-830. PubMed ID: 27834791
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides.
LaFleur DW; Abramyan D; Kanakaraj P; Smith RG; Shah RR; Wang G; Yao XT; Kankanala S; Boyd E; Zaritskaya L; Nam V; Puffer BA; Buasen P; Kaithamana S; Burnette AF; Krishnamurthy R; Patel D; Roschke VV; Kiener PA; Hilbert DM; Barbas CF
MAbs; 2013; 5(2):208-18. PubMed ID: 23575268
[TBL] [Abstract][Full Text] [Related]
8. Cyclization strategies of meditopes: affinity and diffraction studies of meditope-Fab complexes.
Bzymek KP; Ma Y; Avery KA; Horne DA; Williams JC
Acta Crystallogr F Struct Biol Commun; 2016 Jun; 72(Pt 6):434-42. PubMed ID: 27303895
[TBL] [Abstract][Full Text] [Related]
9. Meditope-Fab interaction: threading the hole.
Bzymek KP; Ma Y; Avery KN; Horne DA; Williams JC
Acta Crystallogr F Struct Biol Commun; 2017 Dec; 73(Pt 12):688-694. PubMed ID: 29199990
[TBL] [Abstract][Full Text] [Related]
10. In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor.
Alvarenga ML; Kikhney J; Hannewald J; Metzger AU; Steffens KJ; Bomke J; Krah A; Wegener A
Anal Biochem; 2012 Feb; 421(1):138-51. PubMed ID: 22085444
[TBL] [Abstract][Full Text] [Related]
11. Bacterial production and structure-functional validation of a recombinant antigen-binding fragment (Fab) of an anti-cancer therapeutic antibody targeting epidermal growth factor receptor.
Kim JH; Sim DW; Park D; Jung TG; Lee S; Oh T; Ha JR; Seok SH; Seo MD; Kang HC; Kim YP; Won HS
Appl Microbiol Biotechnol; 2016 Dec; 100(24):10521-10529. PubMed ID: 27470143
[TBL] [Abstract][Full Text] [Related]
12. Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody.
Gerstner RB; Carter P; Lowman HB
J Mol Biol; 2002 Aug; 321(5):851-62. PubMed ID: 12206766
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.
Li S; Kussie P; Ferguson KM
Structure; 2008 Feb; 16(2):216-27. PubMed ID: 18275813
[TBL] [Abstract][Full Text] [Related]
14. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
[TBL] [Abstract][Full Text] [Related]
15. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
Cho HS; Mason K; Ramyar KX; Stanley AM; Gabelli SB; Denney DW; Leahy DJ
Nature; 2003 Feb; 421(6924):756-60. PubMed ID: 12610629
[TBL] [Abstract][Full Text] [Related]
16. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
Merchant M; Ma X; Maun HR; Zheng Z; Peng J; Romero M; Huang A; Yang NY; Nishimura M; Greve J; Santell L; Zhang YW; Su Y; Kaufman DW; Billeci KL; Mai E; Moffat B; Lim A; Duenas ET; Phillips HS; Xiang H; Young JC; Vande Woude GF; Dennis MS; Reilly DE; Schwall RH; Starovasnik MA; Lazarus RA; Yansura DG
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):E2987-96. PubMed ID: 23882082
[TBL] [Abstract][Full Text] [Related]
17. Structural Analysis of Der p 1-Antibody Complexes and Comparison with Complexes of Proteins or Peptides with Monoclonal Antibodies.
Osinski T; Pomés A; Majorek KA; Glesner J; Offermann LR; Vailes LD; Chapman MD; Minor W; Chruszcz M
J Immunol; 2015 Jul; 195(1):307-16. PubMed ID: 26026055
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.
Li S; Schmitz KR; Jeffrey PD; Wiltzius JJ; Kussie P; Ferguson KM
Cancer Cell; 2005 Apr; 7(4):301-11. PubMed ID: 15837620
[TBL] [Abstract][Full Text] [Related]
19. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
[TBL] [Abstract][Full Text] [Related]
20. Structure of anti-FLAG M2 Fab domain and its use in the stabilization of engineered membrane proteins.
Roosild TP; Castronovo S; Choe S
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2006 Sep; 62(Pt 9):835-9. PubMed ID: 16946459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
